Sunil Healthcare Ltd
Incorporated in 1976, Sunil Healthcare Ltd is a certified manufacturer of Empty Hard Gelatin capsules shell and HPMC Capsules shell.[1]
- Market Cap ₹ 63.5 Cr.
- Current Price ₹ 61.9
- High / Low ₹ 88.7 / 56.4
- Stock P/E 16.3
- Book Value ₹ 66.1
- Dividend Yield 0.00 %
- ROCE 6.51 %
- ROE 5.50 %
- Face Value ₹ 10.0
Pros
- Stock is trading at 0.94 times its book value
- Company's working capital requirements have reduced from 23.7 days to 14.4 days
Cons
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -0.49% over past five years.
- Company has a low return on equity of 1.05% over last 3 years.
- Company has high debtors of 182 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 72.64 | 81.63 | 108.95 | 90.22 | 80.93 | 70.13 | 89.89 | 116.37 | 111.83 | 89.69 | 83.42 | 87.72 | |
| 60.57 | 66.75 | 93.21 | 75.52 | 68.45 | 76.58 | 83.68 | 98.55 | 92.52 | 85.24 | 71.45 | 73.76 | |
| Operating Profit | 12.07 | 14.88 | 15.74 | 14.70 | 12.48 | -6.45 | 6.21 | 17.82 | 19.31 | 4.45 | 11.97 | 13.96 |
| OPM % | 16.62% | 18.23% | 14.45% | 16.29% | 15.42% | -9.20% | 6.91% | 15.31% | 17.27% | 4.96% | 14.35% | 15.91% |
| 0.94 | 1.33 | 1.25 | 2.00 | 0.09 | 14.71 | 5.56 | 1.55 | 1.63 | 4.53 | 1.25 | -8.44 | |
| Interest | 2.85 | 4.36 | 4.18 | 5.03 | 6.58 | 6.95 | 5.31 | 3.49 | 4.17 | 5.78 | 6.46 | 6.16 |
| Depreciation | 4.00 | 3.82 | 4.33 | 4.78 | 5.74 | 6.13 | 6.11 | 6.31 | 7.01 | 6.08 | 6.35 | 6.44 |
| Profit before tax | 6.16 | 8.03 | 8.48 | 6.89 | 0.25 | -4.82 | 0.35 | 9.57 | 9.76 | -2.88 | 0.41 | -7.08 |
| Tax % | 35.39% | 34.99% | 33.73% | 22.64% | 28.00% | -13.49% | 22.86% | 29.15% | 28.48% | -27.08% | 48.78% | -25.00% |
| 3.98 | 5.23 | 5.62 | 5.32 | 0.18 | -4.17 | 0.28 | 6.78 | 6.98 | -2.11 | 0.21 | -5.30 | |
| EPS in Rs | 3.88 | 5.10 | 5.48 | 5.19 | 0.18 | -4.07 | 0.27 | 6.61 | 6.81 | -2.06 | 0.20 | -5.17 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 1% |
| 5 Years: | 0% |
| 3 Years: | -8% |
| TTM: | 5% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | -3% |
| 5 Years: | 65% |
| 3 Years: | -17% |
| TTM: | 1241% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | -5% |
| 5 Years: | 15% |
| 3 Years: | 2% |
| 1 Year: | -19% |
| Return on Equity | |
|---|---|
| 10 Years: | 4% |
| 5 Years: | 5% |
| 3 Years: | 1% |
| Last Year: | 6% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 10.25 | 10.25 | 10.25 | 10.25 | 10.25 | 10.25 | 10.25 | 10.25 | 10.25 | 10.25 | 10.25 | 10.25 |
| Reserves | 15.62 | 20.81 | 33.24 | 38.54 | 38.88 | 37.52 | 37.82 | 44.53 | 51.47 | 63.79 | 63.40 | 57.58 |
| 25.16 | 37.06 | 44.53 | 60.62 | 55.08 | 49.45 | 49.82 | 34.68 | 36.79 | 66.15 | 68.65 | 55.79 | |
| 12.51 | 17.66 | 31.33 | 33.18 | 35.50 | 37.19 | 25.68 | 22.73 | 27.57 | 23.70 | 25.91 | 38.70 | |
| Total Liabilities | 63.54 | 85.78 | 119.35 | 142.59 | 139.71 | 134.41 | 123.57 | 112.19 | 126.08 | 163.89 | 168.21 | 162.32 |
| 27.31 | 40.94 | 59.72 | 70.92 | 68.82 | 69.97 | 69.80 | 69.97 | 70.43 | 87.16 | 94.08 | 85.85 | |
| CWIP | 0.77 | 0.06 | 0.12 | 0.19 | 2.47 | 0.01 | 0.01 | 1.75 | 0.01 | 5.66 | 0.09 | 1.77 |
| Investments | 0.00 | 0.00 | 0.00 | 0.23 | 0.24 | 0.24 | 1.20 | 1.16 | 0.00 | 0.00 | 0.00 | 0.00 |
| 35.46 | 44.78 | 59.51 | 71.25 | 68.18 | 64.19 | 52.56 | 39.31 | 55.64 | 71.07 | 74.04 | 74.70 | |
| Total Assets | 63.54 | 85.78 | 119.35 | 142.59 | 139.71 | 134.41 | 123.57 | 112.19 | 126.08 | 163.89 | 168.21 | 162.32 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5.88 | 7.77 | 10.79 | 4.91 | 15.07 | 4.18 | 16.63 | 21.89 | 7.13 | -14.35 | 11.54 | 22.15 | |
| -8.48 | -14.90 | -12.85 | -17.36 | -3.08 | -2.46 | -11.33 | -3.35 | -3.40 | -10.62 | -7.70 | -2.85 | |
| 2.75 | 8.18 | 2.23 | 11.62 | -11.66 | -1.54 | -6.42 | -18.56 | -3.75 | 25.00 | -3.87 | -19.26 | |
| Net Cash Flow | 0.15 | 1.05 | 0.17 | -0.83 | 0.33 | 0.18 | -1.12 | -0.01 | -0.02 | 0.04 | -0.03 | 0.04 |
| Free Cash Flow | -1.93 | -6.69 | -2.15 | -10.75 | 9.56 | 3.50 | 9.92 | 12.87 | 3.65 | -24.53 | 2.54 | 18.60 |
| CFO/OP | 75% | 65% | 79% | 43% | 123% | -66% | 265% | 129% | 44% | -305% | 96% | 159% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 99.39 | 107.94 | 130.49 | 194.11 | 186.63 | 149.01 | 112.84 | 69.00 | 115.90 | 192.37 | 212.21 | 181.79 |
| Inventory Days | 109.32 | 134.28 | 74.03 | 98.26 | 185.09 | 283.19 | 95.96 | 76.84 | 97.03 | 98.42 | 162.94 | 216.53 |
| Days Payable | 80.62 | 106.03 | 137.66 | 180.38 | 280.22 | 297.33 | 107.97 | 64.07 | 112.06 | 44.74 | 83.51 | 180.82 |
| Cash Conversion Cycle | 128.09 | 136.18 | 66.86 | 111.99 | 91.50 | 134.87 | 100.83 | 81.77 | 100.87 | 246.04 | 291.63 | 217.50 |
| Working Capital Days | 6.93 | -6.57 | -9.65 | -11.00 | -40.23 | -46.79 | -34.72 | -11.07 | 16.25 | 30.24 | 26.38 | 14.36 |
| ROCE % | 19.19% | 20.80% | 16.37% | 12.08% | 6.39% | 2.38% | 5.84% | 13.88% | 14.73% | 2.57% | 4.93% | 6.51% |
Insights
In beta| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Installed Capacity Billion Capsules per annum |
|
|||||||||||
| Capacity Utilization % |
||||||||||||
| Production Volume Million Capsules |
||||||||||||
| Sales Volume Million Capsules |
||||||||||||
| Number of Capsule Sizes (SKUs) Count |
||||||||||||
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
31 May - Copy of newspaper publication dated 31.05.2026 of the financial results for the quarter/year ended 31.03.206
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
30 May - Submitted Annual Secretarial Compliance Report for FY 2025-26 dated 29.05.2026.
-
Board Meeting Outcome for Outcome Of The 269Th Board Meeting Of The Company Held On 29.05.2026.
29 May - Board approved FY26 audited standalone and consolidated results, no dividend, appointed internal auditor, and adopted board report.
-
Approved Audited Financial Results (Standalone And Consolidated) For The Quarter/Year Ended March 31, 2026
29 May - Board approved FY26 audited standalone and consolidated results, no dividend, appointed internal auditor.
-
Approved Audited Financial Results (Standalone And Consolidated) For The Quarter/Year Ended March 31, 2026
29 May - Board approved FY26 audited results, no dividend, internal auditor appointment, and Board Report on May 29, 2026.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Concalls
-
Nov 2018TranscriptAI SummaryPPT
-
Sep 2018TranscriptAI SummaryPPT
-
May 2018TranscriptAI SummaryPPT
-
May 2018TranscriptAI SummaryPPT
-
Feb 2018TranscriptAI SummaryPPT
-
Feb 2018TranscriptAI SummaryPPT
-
Dec 2017TranscriptAI SummaryPPT
-
Aug 2017TranscriptAI SummaryPPT
-
May 2017TranscriptAI SummaryPPT
-
Feb 2017TranscriptAI SummaryPPT
-
Nov 2016TranscriptAI SummaryPPT
-
Aug 2016TranscriptAI SummaryPPT
-
May 2016TranscriptAI SummaryPPT
-
Mar 2016TranscriptAI SummaryPPT
Business Overview:[1][2]
a) SHL was earlier engaged in trading (including merchant trading) agro based commodities, under brand Sunloc foods However, this was discontinued in FY20
b) Currently, it is mainly engaged in the manufacturing empty hard gelatin capsule (EHGC) shells and hydroxypropyl methyl cellulose (HPMC) and the choice in 9 sizes available are 00, 0SEL, 0EL, 0,1, 2, 3, 4, 5.
c) The company is a Hard-shell capsule manufacturer in India and pioneer in double lock and triple lock technology for capsules in India.
d) The company is WHO-GMP certified company and has also been recognized as Star Export House by GOI.